Clinical Impact of Tumor-Infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma

  • Tomoya Sudo
  • Ryosuke Nishida
  • Akihiko Kawahara
  • Kouhei Saisho
  • Koshi Mimori
  • Akira Yamada
  • Atsuhi Mizoguchi
  • Kazutaka Kadoya
  • Satoru Matono
  • Naoki Mori
  • Toshiaki Tanaka
  • Yoshito Akagi
Translational Research and Biomarkers

DOI: 10.1245/s10434-017-5796-4

Cite this article as:
Sudo, T., Nishida, R., Kawahara, A. et al. Ann Surg Oncol (2017). doi:10.1245/s10434-017-5796-4
  • 53 Downloads

Abstract

Background

Recently, several immune checkpoint inhibitors have been developed and are being used to treat malignant melanoma, lung cancer, and other cancers. Several reports have indicated that tumor-infiltrating lymphocytes (TILs) are associated with clinical and histopathologic risk factors in various cancers. However, the role of TILs in esophageal squamous cell carcinoma (ESCC) has not been well studied. This study aimed to investigate the perilesional status of TILs in ESCC and to show associations between TILs and clinical variables.

Methods

The study enrolled 277 ESCC patients. Evaluation of TILs was performed according to the criteria of the International TILs Working Group 2014, and associations between TIL and clinicopathologic variables were examined.

Results

Most of the clinicopathologic factors were not statistically associated with TIL status. The number of patients who received adjuvant therapy was significantly larger in the TIL-negative group. Cancer-specific survival (CSS) of patients in the TIL-positive group was significantly better than in the TIL-negative group. Among the patients who received adjuvant therapy, CSS was significantly better in the TIL-positive group than in the TIL-negative group. Uni- and multivariate analyses identified tumor depth and TIL status as independent prognostic factors for CSS. Among the other clinicopathologic variables, TIL status was the strongest CSS indicator.

Conclusion

Tumor-infiltrating lymphocyte status is a strong predictor of good prognosis for ESCC patients.

Supplementary material

10434_2017_5796_MOESM1_ESM.docx (17 kb)
Supplementary Table 1 (DOCX 17 kb)
10434_2017_5796_MOESM2_ESM.pptx (41 kb)
Chi-squared test between TIL and pathological disease staging. A p-value <0.05 was considered to be statistically significant. Supplementary Figure 1 (PPTX 40 kb)
10434_2017_5796_MOESM3_ESM.pptx (42 kb)
Cancer specific survival (CSS) comparison by TIL status. Differences in CSS were assessedusing the Kaplan-Meier method and compared using the log-rank test. Comparison of CSS in patients who received neoadjuvant therapy. A p-value < 0.05 was considered to be statistically significant. Supplementary Figure 2 (PPTX 41 kb)

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Tomoya Sudo
    • 1
    • 2
  • Ryosuke Nishida
    • 1
  • Akihiko Kawahara
    • 3
  • Kouhei Saisho
    • 1
    • 2
  • Koshi Mimori
    • 4
  • Akira Yamada
    • 3
  • Atsuhi Mizoguchi
    • 5
  • Kazutaka Kadoya
    • 1
  • Satoru Matono
    • 1
  • Naoki Mori
    • 1
  • Toshiaki Tanaka
    • 1
  • Yoshito Akagi
    • 1
  1. 1.Department of SurgeryKurume University School of MedicineKurumeJapan
  2. 2.Research Center for Innovative Cancer TherapyKurume University School of MedicineKurumeJapan
  3. 3.Department of Diagnostic PathologyKurume University HospitalKurumeJapan
  4. 4.Department of Surgery Tsurumihira 4546Kyushu University, Beppu HospitalBeppu, OitaJapan
  5. 5.Department of ImmunologyKurumeJapan